Profile image
Story Views

Last Hour:
Last 24 Hours:

Leukemia Therapeutics Market 2016 Analysis and Forecast 2020

Thursday, February 9, 2017 3:10
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Cancer that starts from hematopoietic stem cells of the bone marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. Also, based on the bone marrow cells from which cancer starts, leukemia can be categorized as lymphocytic or myeloid.

Publisher’s analysts forecast the leukemia therapeutics market to grow at a CAGR of 8.44% during the period 2016-2020.

For more information about this report:  

Covered in this report 
The report covers the present scenario and the growth prospects of the leukemia therapeutics market for 2016-2020. To calculate the market size, the report considers the the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of different types of leukemias.

The market is divided into the following segments based on geography: 
- Americas

Publisher’s report, Leukemia Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
- F. Hoffmann-La Roche
- Novartis
- Bristol-Myers Squibb
- AbbVie
- Teva Pharmaceuticals


Request Sample Copy at            


Other prominent vendors 
- Altor BioScience
- Amgen
- ARIAD Pharmaceuticals
- Arno Therapeutics
- Astex Pharmaceuticals
- AstraZeneca
- Baxter Healthcare
- Bayer HealthCare
- Bellicum Pharmaceuticals
- Biogen
- Boehringer Ingelheim
- BioLineRx
- Boston Biomedical
- Celator Pharmaceuticals
- Celgene
- CTI BioPharma
- Chroma Therapeutics
- Chugai Pharmaceutical
- Cyclacel Pharmaceuticals
- Daiichi Sankyo
- Eisai
- Emergent BioSolutions
- Erytech Pharma
- Fate Therapeutics
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- iDD biotech
- Immune Pharmaceuticals
- Immunomedics
- Infinity Pharmaceuticals
- Innate Pharma
- Jazz Pharmaceuticals
- Juno Therapeutics
- Karyopharm Therapeutics
- Ligand Pharmaceuticals
- MEDA Pharmaceuticals
- MedImmune
- Merck
- Midas Pharma
- Molecular Templates
- MorphoSys
- Nippon Shinyaku
- Novo Nordisk
- Onconova Therapeutics
- Ono Pharmaceuticals
- Orphan Europe
- Otsuka
- Pfizer
- Portola Pharmaceuticals
- Regeneron Pharmaceuticals
- Sanofi
- Sigma-Tau Pharmaceuticals
- Stemline Therapeutics
- Sunesis Pharmaceuticals
- TG Therapeutics
- TheraMAB
- Tolero Pharmaceuticals
- XEME Biopharma
- Xencor
- ZIOPHARM Oncology

Market driver 
- Technological advances in the monitoring of leukemia
- For a full, detailed list, view our report 

Market challenge 
- Limitations associated with current therapeutic options
- For a full, detailed list, view our report 

Market trend 
- Rise in the development of combination therapies
- For a full, detailed list, view our report 

Inquire for Report at          

Contact Us:

Call: +1-646-491-9876

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.